Jon I. C.
- Country
- Spain
- Department
- Neurology
Research Overview
- Phase 1b/2a First‑in‑Human Randomized, Double‑Blind, Placebo‑Controlled, Multiple Ascending Intrathecal Dose Study of S233107 in Patients with Spinocerebellar Ataxia Type 3
- Efficacy and Safety Evaluation of BIIB122 in a Randomized, Double-Blind, Placebo-Controlled Phase 2b Study in Parkinson's Disease Patients
- Efficacy and Safety of Donepezil Hydrochloride in Mild Cognitive Impairment Associated with Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled Trial
Data & Insights
Has run more than one trial at 11 of 64 partner sites.
Specializations
Neurodegenerative Disorders
The investigator specializes in treating Parkinson's disease and its associated complications, with particular emphasis on innovative therapeutic approaches.
- LRRK2-associated Parkinson's Disease
- Novel therapeutic interventions
- Disease progression monitoring
Their research encompasses genetic forms of Parkinson's disease, specifically focusing on LRRK2 mutations and their therapeutic implications.
Cognitive Function
The investigator explores the relationship between cognitive impairment and Parkinson's disease, investigating therapeutic solutions for cognitive decline.
- Mild cognitive impairment in Parkinson's
- Cognitive performance assessment
- Cholinergic therapy evaluation
Their work extends to evaluating cognitive enhancement strategies in Parkinson's disease patients.
Clinical Therapeutics
The investigator conducts research on disease-modifying treatments and symptomatic therapies for Parkinson's disease.
- Safety and efficacy assessments
- Long-term treatment outcomes
- Novel drug development
Their expertise includes evaluating therapeutic interventions through controlled clinical trials with various treatment modalities.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.